Park Medi World Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Record year, capacity-led growth: FY26 delivered the company's best-ever operating and financial performance, driven by record patient volumes and the largest single-year bed addition in its history (610 beds).
• Acquisition engine is self-funding: The ~INR1,000 crores deployed in acquisitions to date generated ~INR1,100 crores of revenue in FY26 alone, implying a payback period of roughly 11 months on a revenue basis.
• Brownfield units break even instantly: Newly commissioned brownfield units in Agra and Bathinda turned EBITDA-positive and PAT-positive in their first month of operation, a stark contrast to the 12-15 month break-even for greenfield projects.
• Margins benefit from high occupancy, not price: Q4 margin expansion came from occupancy gains at mature hospitals; management explicitly keeps ARPOB within an affordable range and does not treat it as the primary profit lever.
• What to watch next quarter: The actual revenue impact of the ~7-7.5% CGHS rate revision, which management expects to flow through in full only after Q1 FY27, and the pace of the Narela Delhi commissioning targeted for Q2.

Capacity Expansion: The Bed Pipeline

• Record addition in FY26: 610 beds were added, the largest single-year capacity expansion in the company's history, comprising the 250-bed Bathinda brownfield and the 360-bed Agra unit.
• Panchkula greenfield live: The largest-ever greenfield facility, a 350-bed hospital in Panchkula built at a capex of INR125 crores, was commissioned on 10th April 2026.
• Narela Delhi next in line: A 200-bed hospital in Narela, Delhi was acquired under the IBC process; INR55 crores of the INR80 crores total capex has already been spent, with commissioning targeted for Q2 FY27.
• FY27-28 pipeline mapped: 850 beds planned for FY27 (350 Panchkula already done, 200 Narela, 300 Kanpur) and 1,000 beds for FY28 (400 Gorakhpur, 200 Ambala oncology extension, 150 Mohali expansion, 250 Rohtak greenfield). Total capex for the next two years is pegged at ~INR500 crores, well within internal resources given FDs of INR314 crores, INR100 crores in the bank, and annual OCF of INR330 crores.
• Long-term ambition: Management hopes to double bed strength from the targeted 5,460 by March 2028 to nearly 10,000+ between FY28 and FY33, and to expand geographically beyond the current 16 North Indian districts into the South, East, and West.
• Capex efficiency is a structural advantage: On a consolidated basis through FY28, capex per bed is estimated at ~INR34 lakhs, which management claims is less than half the nearest competitor's cost, achieved by accommodating more beds in less space while maintaining NABH compliance.

Sanjay Sharma: "I don't foresee any other hospital with such low capex and delivering such good results with affordable ARPOB and excellent clinical outcomes."

Acquisition Strategy & Integration

• Distress is the entry point: The acquisition filter targets five criteria: strategic location, domain strength of the region, available or missing medical facilities, headroom for expandability, and distress assets that are bleeding profusely, enabling deep discounting. Because the assets are already bleeding, EV-EBITDA multiples are irrelevant to the purchase decision.
• Revenue payback in under a year: Total capex and sales consideration for acquisitions so far is about INR1,000 crores. The contribution of acquired assets to FY26 revenue was about 61%, or roughly INR1,100 crores, meaning the investment deployed was recovered in terms of revenue realized in approximately 11 months. Weighted-average EBITDA break-even sits between three and three-and-a-half years.
• Brownfield vs. greenfield economics diverge sharply: Greenfield projects historically take four to six months to reach break-even and two-and-a-half to three years for full recovery, typically touching EBITDA-positive but not PAT-positive in year one. Brownfield units like Bathinda and Agra, by contrast, achieved EBITDA-positive and PAT-positive status in their very first month of operation.
• Integration is swift and selective: When acquiring distressed units, efficient staff are retained while underperforming staff and management are replaced. The Agra deal, which was not even under discussion when the company listed on 17th December, was closed by 1st February, a turnaround of roughly 30-35 days.

Rajesh Sharma: "When we did our listed on 17th of December, there was no way Agra discussion was. But we ended up closing that deal from 1st of Feb. So this all happen on a period of, you can say about 30-35 days."

Payor Mix & Receivables

• Mix shifting toward government insurance: The payor mix is changing due to increasing preference from the cash TPA segment. Management targets a 65-70% government insurance and ~30% private insurance split by the end of FY27, stabilizing in a 70-30 band over the next 12 to 18 months.
• Collections are near-perfect: Collections are running at nearly 100% on a ballpark basis, dispelling concerns about government insurance receivables. The working capital cycle and receivable cycle have both seen a sharp reduction despite nearly 21% growth in realisable revenue.
• Debtor days improving structurally: Debtor days improved to 129 days for FY26, driven by a government push to streamline bill settlement. The process requires bills to be uploaded within 7 days of discharge, after which a third-party service provider has a 3-month window to clear the bill, plus 45 days for payment. The government is pushing to reduce that 3-month window to 2 months. Management expects debtor days to remain within a 4-month range and does not foresee a drop below 100 days in the next six to nine months, though it may happen by the current or next financial year.
• Disallowance provision held steady: The provision for disallowance remained at 9% in Q4; management describes a rigorous internal process to reduce it further.

Revenue Drivers & Segment Trends

• Oncology gaining share: Oncology's contribution to revenue rose from 6% in Q4 FY25 to 8% in Q4 FY26, and from 5% to 6.5% on an annual basis. An Ambala oncology extension of 200 beds is in the pipeline.
• CGHS rate revision to lift FY27: A CGHS rate revision has begun to flow through, but management expects the full impact, an appreciation of about 7-7.5% to revenue on a conservative basis perhaps 5-6% net, to be visible only after Q1 FY27.
• Agra to contribute INR90 crores in FY27: The Agra unit, commissioned in February 2026 and already adding close to INR5 crores per month to the top line, is expected to contribute about INR90 crores in FY27 and become EBITDA-positive, though not a material contributor to EBITDA margin.
• Tier-2/3 demand is surging: There is no demand-side problem in Tier-2 and Tier-3 cities; patients who previously traveled to metros and lost the golden hour in critical illness are now served locally. Top-end doctors are willing to work in these cities because Park provides the necessary structure and facilities.
• Standalone revenue drop is a consolidation artifact: The QoQ drop in Park Medi World standalone revenue reflects the Bathinda hospital, previously run under an O&M contract and consolidated in Park Medi World's revenue, being acquired on 5th January and becoming an independent subsidiary. There is no impact on the consolidated top line.

Sanjay Sharma: "Yes, some flowing of that rate has come in, but actual impact probably will be seen after the Q1 FY'27, to be honest, in the complete format."

Cost Structure & Margin Levers

• ARPOB is deliberately constrained: Management views ARPOB as only one factor in profitability and growth, and deliberately keeps it within an affordable range because the company's total addressable market is the ~130-crore affordable segment.
• Expenses should be benchmarked to revenue, not ARPOB: When challenged on how to manage cost inflation of ~8%+ in doctor salaries and consumables against ARPOB growth of only 5-6%, management redirected the analysis, arguing expenses must be evaluated as a percentage of revenue and profitability, not ARPOB alone.
• Structural cost advantages stack up: The company cites the lowest capex per bed in the industry, excellent vendor management with no debtors beyond one month and vendor debts cleared by the 10th-15th of the next month yielding significant discounting, and a dedicated in-house construction unit that accelerates renovations and new builds.
• CGHS oncology pricing managed through vendor negotiation: When oncology rates were to be subsidized for cancer patients under CGHS, the company held prolonged joint meetings with vendors and agreed to provide treatment at very low negotiated rates with minimal profits.

Sudesh Sharma: "So a humble request, a suggestion, please see expenses as a percentage in terms of how they relate to the revenue, profitability numbers, not ARPOB alone."

People & Clinical Model

• Doctor attrition is among the lowest in the industry: The selection process is methodical; doctors are paid well and their families are accommodated. Critically, doctors are not held accountable for volume or revenue, only for patient and attendant satisfaction and excellent clinical outcomes. A percentile clocking system rewards clinicians above the 75th percentile with a performance bonus from the promoters.
• NABH and NABL accreditation expanding: 15 hospitals now hold NABH accreditation, with the newly commissioned Panchkula hospital set to enter the process shortly. Eight laboratories carry NABL accreditation, and five additional laboratories are being planned for the same.

Sanjay Sharma: "These doctors are accountable only on two major verticals. One is patient and attendant satisfaction and the other is excellent clinical outcomes."

Guidance & Commitments

Key Metrics